Understanding ACIP’s New Recommendations on RSV Prevention and Safety

Advancements in RSV Prevention: A New Recommendation from ACIP

In June 2025, the CDC’s Advisory Committee on Immunization Practices (ACIP) took a significant step in public health by recommending a second monoclonal antibody to combat respiratory syncytial virus (RSV) for infants. The new treatment, clesrovimab, will complement the previously approved nirsevimab and provide a vital tool in preventing this severe illness, which burdens many children under the age of five.

The Challenge of RSV in Young Children

RSV is a major cause of hospitalization among infants, with around 97% of children contracting the virus before turning two. According to Dr. Adam MacNeil from the CDC, the availability of two preventive monoclonal antibodies represents a monumental victory against an illness that can lead to severe respiratory complications. This dual approach aims not only to provide greater access to treatments but also to alleviate supply issues that might arise.

Safety Concerns and Recommendations

Interestingly, not all members of ACIP unanimously endorsed clesrovimab. Five voting members cited safety concerns as a key factor in their decision against the recommendation. In contrast, nirsevimab has a proven record for preventing severe RSV disease in high-risk infants. It highlights the importance of rigorous discussions surrounding vaccine safety and effectiveness, ensuring that public health does not compromise the well-being of the youngest patients.

Clinical Perspectives on Vaccine Safety

The importance of vaccination was echoed during public commentary at the ACIP meeting. Many clinicians emphasized that vaccines are essential in protecting children from preventable diseases. Dr. Caroline Brown, a pediatrician from North Carolina, expressed concern for the rise of vaccine-preventable diseases like measles and reiterated the extensive research confirming the safety and efficacy of vaccines.

Continued Efforts Against RSV

Lori Handy, MD, MSCE, highlighted that the continued promotion of the RSV vaccine has the potential to considerably reduce hospitalizations among infants. The dual-use of maternal vaccines and monoclonal antibodies over the past two seasons has shown promising results, and maintaining this momentum is critical as seasonal outbreaks arise.

Looking Ahead: What These Recommendations Mean

The introduction of clesrovimab is viewed as a significant advancement in pediatric healthcare. With ongoing discussions about safety, public health officials and healthcare providers have an opportunity to bridge information gaps. Open dialogues will help build confidence among parents regarding both existing and new preventive measures against RSV. As the science of immunization evolves, the capacity to protect vulnerable populations continues to grow, paving the way for healthier futures for our children.

As we look to the future, it is imperative for parents and caregivers to stay informed about these developments in RSV prevention and how they can take proactive steps in protecting their children’s health. Given the significant burden of RSV, understanding the available tools and recommendations can guide better health outcomes.